Beneficial effect of 5‐HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of α‐synuclein
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Alok Shiomurti Tripathi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Era College of Pharmacy, ERA University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Serotonin 5-HT1 Receptor Agonists, Parkinson Disease, Tryptamines, Oxazolidinones. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
The given investigation examined the neuroprotection role of 5‐HT1b/1d agonist in reserpine induced Parkinson's disease (PD) in male Wistar rats. PD was induced in rats by reserpine at 5 mg/kg ip for 3 days and thereafter the rats were provided with the following treatments for 4 days, zolmitriptan (ZLM) group (30 mg/kg ip); STD group (levodopa + carbidopa, 200 + 5 mg/kg ip); ZLM + GA group (zolmitriptan, 30 mg/kg ip and glutamic acid, 1.5 mg/kg); ZLM + DX group (zolmitriptan, 30 mg/kg ip and dextromethorphan, 20 mg/kg ip). All the groups were then assessed for cognitive and motor functions at the end of the protocol. Moreover, oxidative stress parameters and histopathological changes were observed in rats of all treatment groups. Deposition of α‐synuclein in the brain tissue was observed by silver staining. Data of this investigation revealed that motor and cognitive functions were improved in the ZLM‐treated group compared with the negative control group, which was observed to be reversed in ZLM + GA group. Treatment with ZLM ameliorated oxidative stress and histopathological changes in the brain tissue of PD rats. Further, ZLM reduced the deposition of α‐synuclein in PD rats, which reversed in ZLM + GA‐treated group. This study concludes by stating that 5‐HT1b/1d agonist can prevent neurodegeneration and reduce oxidative stress in PD rats. The probable underlying mechanism of such an effect of 5‐HT1b/1d agonist could be by regulating the deposition of α‐synuclein and reducing the expression of NMDA receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Era College of Pharmacy, ERA University, Lucknow, Uttar Pradesh, India.
- Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University, Noida, Uttar Pradesh, India.
- Department of Pharmacology, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Gujarat, India.
- Department of Chemistry, College of Science, Imam Mohammad lbn Saud Islamic University, Riyadh, Saudi Arabia.
Zitieren
APA
Tripathi, A. S., Fatima, N., Tripathi, P., Tripathi, R., Alka, Zaki, M. E. A., Mohapatra, L., Yasir, M., & Maurya, R. K. (2024). Beneficial effect of 5‐HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of α‐synuclein. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23627
Vancouver
Tripathi AS, Fatima N, Tripathi P, Tripathi R, Alka, Zaki MEA, et al. Beneficial effect of 5‐HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of α‐synuclein. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23627
BibTeX
@article{Tripathi2024,
author = {Tripathi, Alok Shiomurti and Fatima, Needa and Tripathi, Pankaj and Tripathi, Rina and Alka and Zaki, Magdi E A and Mohapatra, Lucy and Yasir, Mohammad and Maurya, Rahul K},
title = {Beneficial effect of 5‐HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of α‐synuclein},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23627}
}
EUVIMED